Jennifer Fine

3.8k total citations · 3 hit papers
43 papers, 2.8k citations indexed

About

Jennifer Fine is a scholar working on Cardiology and Cardiovascular Medicine, Epidemiology and Ophthalmology. According to data from OpenAlex, Jennifer Fine has authored 43 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cardiology and Cardiovascular Medicine, 11 papers in Epidemiology and 9 papers in Ophthalmology. Recurrent topics in Jennifer Fine's work include Cardiomyopathy and Myosin Studies (11 papers), Retinal Diseases and Treatments (8 papers) and Cardiovascular Function and Risk Factors (7 papers). Jennifer Fine is often cited by papers focused on Cardiomyopathy and Myosin Studies (11 papers), Retinal Diseases and Treatments (8 papers) and Cardiovascular Function and Risk Factors (7 papers). Jennifer Fine collaborates with scholars based in United States, South Africa and United Kingdom. Jennifer Fine's co-authors include Chantal Dolan, Neil M. Bressler, PK Shah, John J. López, Raymond L. Benza, George R. McKendall, Timothy D. Henry, Daniel S. Berman, Brian H. Annex and Frank J. Giordano and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Jennifer Fine

43 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The VIVA Trial

2003 796 citations Jennifer Fine et al. profile →
Prevalence of and Risk Factors for Diabetic Macular Edema in the United States

2014 298 citations Rohit Varma, Neil M. Bressler et al. profile →
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

2021 127 citations John A. Spertus, Jennifer Fine et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jennifer Fine United States	19	684	604	577	478	455	43	2.8k
Deidre Anne De Silva Singapore	35	648 0.9×	350 0.6×	703 1.2×	1.2k 2.4×	246 0.5×	151	5.0k
J.J. Heimans Netherlands	39	529 0.8×	114 0.2×	711 1.2×	788 1.6×	455 1.0×	98	5.5k
Monika Baier United States	34	562 0.8×	802 1.3×	241 0.4×	673 1.4×	361 0.8×	60	4.5k
Chung‐Ching Chio Taiwan	37	937 1.4×	115 0.2×	161 0.3×	1.0k 2.1×	434 1.0×	129	3.7k
Ying Guo United States	29	724 1.1×	369 0.6×	133 0.2×	112 0.2×	334 0.7×	127	2.3k
Maria Laura Manca Italy	25	623 0.9×	172 0.3×	237 0.4×	621 1.3×	148 0.3×	80	2.3k
John G Lawrenson United Kingdom	33	642 0.9×	1.7k 2.9×	1.2k 2.2×	116 0.2×	110 0.2×	136	3.7k
Dana Leifer United States	25	798 1.2×	153 0.3×	226 0.4×	621 1.3×	336 0.7×	48	2.8k
Andrea Pace Italy	39	527 0.8×	57 0.1×	399 0.7×	645 1.3×	479 1.1×	170	4.7k
Sophia Y. Wang United States	27	490 0.7×	939 1.6×	811 1.4×	215 0.4×	118 0.3×	101	2.7k

Countries citing papers authored by Jennifer Fine

Since Specialization

Citations

This map shows the geographic impact of Jennifer Fine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Fine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Fine more than expected).

Fields of papers citing papers by Jennifer Fine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Fine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Fine. The network helps show where Jennifer Fine may publish in the future.

Co-authorship network of co-authors of Jennifer Fine

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Fine. A scholar is included among the top collaborators of Jennifer Fine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Fine. Jennifer Fine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Desai, Nihar R., Jipan Xie, Jennifer Fine, et al.. (2023). Clinical Outcomes, Resource Utilization, and Treatment Over the Disease Course of Symptomatic Obstructive Hypertrophic Cardiomyopathy in the United States. The American Journal of Cardiology. 192. 16–23. 5 indexed citations

Edwards, Teresa, Jennifer Fine, Susan Martin, et al.. (2023). Side effects and impacts of extended adjuvant endocrine therapy: A qualitative study among women with HR+/HER2- breast cancer.. Journal of Clinical Oncology. 41(16_suppl). e12509–e12509. 1 indexed citations

Reaney, Matthew, et al.. (2022). Longitudinal Psychometric Analysis of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) Using Outcomes from the Phase III EXPLORER-HCM Trial. PharmacoEconomics - Open. 6(4). 575–586. 2 indexed citations

Owens, Anjali, Wei Gao, Jennifer Fine, et al.. (2022). Treatment Changes, Healthcare Resource Utilization, and Costs Among Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Claims Database Study. Cardiology and Therapy. 11(2). 249–267. 13 indexed citations

Nassif, Michael E., Jennifer Fine, Chantal Dolan, et al.. (2022). Validation of the Kansas City Cardiomyopathy Questionnaire in Symptomatic Obstructive Hypertrophic Cardiomyopathy. JACC Heart Failure. 10(8). 531–539. 39 indexed citations

Jain, Sneha S., Jipan Xie, Jennifer Fine, et al.. (2021). Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States. Journal of Medical Economics. 24(1). 1115–1123. 24 indexed citations

Fine, Jennifer, et al.. (2018). MOdified NARanjo Causality Scale for ICSRs (MONARCSi): A Decision Support Tool for Safety Scientists. Drug Safety. 41(11). 1073–1085. 24 indexed citations

Fine, Jennifer, et al.. (2014). A survey on the treatment of atrial fibrillation in South Africa. South African Medical Journal. 104(9). 623–623. 13 indexed citations

Bressler, Neil M., Tom Chang, Rohit Varma, et al.. (2012). Driving Ability Reported by Neovascular Age-related Macular Degeneration Patients after Treatment with Ranibizumab. Ophthalmology. 120(1). 160–168. 18 indexed citations

10.

Trenkwalder, Claudia, Bryan Kies, Monika Rudzińska, et al.. (2010). Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study (RECOVER). Movement Disorders. 26(1). 90–99. 326 indexed citations

11.

Myers, Jonathan E., et al.. (2009). Estimating the prevalence of clinical manganism using a cascaded screening process in a South African manganese smelter. NeuroToxicology. 30(6). 934–940. 12 indexed citations

12.

Bressler, Neil M., et al.. (2008). Self-Reported Perception of Driving Function After Ranibizumab Therapy in Patients With Neovascular Age-Related Macular Degeneration (AMD). Investigative Ophthalmology & Visual Science. 49(13). 5578–5578. 2 indexed citations

13.

Chang, Tom, et al.. (2007). Self-Reported Perception of Driving Function Following Ranibizumab Treatment in Patients With Neovascular AMD. Investigative Ophthalmology & Visual Science. 48(13). 1830–1830. 3 indexed citations

14.

Suñer, Iván J., et al.. (2007). Vision-Related Function After Ranibizumab Treatment by Better- or Worse-Seeing Eye: 24 Month Results From MARINA. Investigative Ophthalmology & Visual Science. 48(13). 1808–1808. 3 indexed citations

15.

Schwartz, Stephen G., et al.. (2007). Patient-Reported Visual Function Over 24 Months in Predominantly Classic Neovascular AMD: Results From ANCHOR, a Phase III Trial of Ranibizumab and Verteporfin PDT. Investigative Ophthalmology & Visual Science. 48(13). 1822–1822. 3 indexed citations

16.

Bressler, Neil M., Jennifer Fine, James Ward, et al.. (2007). Relationship Between Patient-Reported Visual Function and Visual Acuity in Subjects With Neovascular AMD. Investigative Ophthalmology & Visual Science. 48(13). 1174–1174. 2 indexed citations

17.

Chang, Tom, et al.. (2004). longitudinal changes in self–reported visual functioningin AMD patients In a randomized controlled Phase I/II trial of lucentisTM (ranizumab; rHuFAB v2). Investigative Ophthalmology & Visual Science. 45(13). 3098–3098. 5 indexed citations

18.

Kandzari, David E., Eric L. Eisenstein, Nancy E. Clapp‐Channing, et al.. (2001). Advanced coronary artery disease: Appropriate end points for trials of novel therapies. American Heart Journal. 142(5). 843–851. 21 indexed citations

19.

Fine, Jennifer, et al.. (2000). Long-Term Follow-up of Unilateral Pallidotomy in Advanced Parkinson's Disease. New England Journal of Medicine. 342(23). 1708–1714. 185 indexed citations

20.

Fine, Jennifer. (1999). A Prospective Study of Weight Change and Health-Related Quality of Life in Women. JAMA. 282(22). 2136–2136. 340 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact